Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center)

N/A

Report date: 2023/11/16 20:00:38

Base Information

Drug NameAutologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsCD22 modulators
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsNeoplasm, ResidualLymphoma, B-CellLymphoma, Non-Hodgkin +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsLymphoma, B-CellLymphoma, Non-HodgkinPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma +[5] 
Inactive IndicationsNeoplasm, ResidualLeukemia, Lymphocytic, Chronic, B-CellLeukemia, Lymphoid

Other Information

ATC CodeN/A
Related LinksN/A